Australija - anglų - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; macrogol 6000; titanium dioxide; povidone; magnesium stearate; maize starch; propylene glycol; sodium starch glycollate; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - furosemide, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; sodium chloride - oedema: furosemide ? aft is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. it is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.,furosemide ? aft injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide ? aft is indicated by the intravenous route. parenteral use should be replaced with oral furosemide as soon as practical.

Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

loremo pty ltd t/a cyndan manufacturing - ammonium thiocyanate | amitrole - herbicide - buildings - around | commercial/industrial land | drain | margins of dams, lakes and streams | non-agricultural area - general | - african daisy | apple-of-sodom | artichoke thistle | blackberry | chilean cestrum | common heliotrope | common reed or phragmites | couch | creeping/russian knapweed,hardhead | cumbungi | dock | fennel | furze or gorse | hoary cress or whiteweed | illyrian thistle | khaki weed | kikuyu grass | nutgrass | onion weed | ox-eye daisy | prairie ground cherry | sorrel | soursob or oxalis | water couch | water hyacinth | watsonia | yorkshire fog grass | acetosella vulgaris | african wood sorrel | alternanthera repens | asphodel | bermuda buttercup | blackberry with st john's wort | broadleaf cumbungi | broadleaf dock | bullrush | bulrush | cardoon | caterpillar weed | cat's tail | curled dock | european heliotrope | fog grass | green cestrum | green poisonberry | hardhead thistle | heliotrope | maranda | marguerite daisy | miranda | narrowleaf cumbungi | onion grass | paspalum paspalodes | potato weed | red sorrel | rumex brownii | rumex crispus | rumex obtusifolius | sheep sorrel | sheep's sorrel | sodom | soft rus

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; propylene glycol; macrogol 6000; purified talc; sodium starch glycollate type a - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: maize starch; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; propylene glycol; macrogol 6000; purified talc; sodium starch glycollate type a - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; propylene glycol; macrogol 6000; purified talc; sodium starch glycollate type a - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. for adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.